Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?

被引：4
作者：
Congly, S. E. [1 ]
Lee, S. S. [1 ]
机构：
[1] Univ Calgary, Dept Med, Div Gastroenterol, Liver Unit, Calgary, AB, Canada
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2014年 / 40卷 / 08期
关键词：
TREATMENT-NAIVE PATIENTS; COST-EFFECTIVENESS ANALYSIS; INTERFERON-ALPHA; 2A; PLUS RIBAVIRIN; DOUBLE-BLIND; VIRUS; INFECTION; SOFOSBUVIR; SIMEPREVIR; PHASE-3;
D O I：
10.1111/apt.12927
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：983 / 984
页数：2
相关论文
共 10 条
[1]  
Canadian Agency for Drugs and Technologies in Health, DIR ACT ANT AG CHRON, P1
[2]   Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141) [J].
Deuffic-Burban, Sylvie ;
Schwarzinger, Michael ;
Obach, Dorothee ;
Mallet, Vincent ;
Pol, Stanislas ;
Pageaux, Georges-Philippe ;
Canva, Valerie ;
Deltenre, Pierre ;
Roudot-Thoraval, Francoise ;
Larrey, Dominique ;
Dhumeaux, Daniel ;
Mathurin, Philippe ;
Yazdanpanah, Yazdan .
JOURNAL OF HEPATOLOGY, 2014, 61 (01) :7-14
[3]   Cost Analysis of Sofosbuvir/Ribavirin Versus Sofosbuvir/Simeprevir for Genotype 1 Hepatitis C Virus in Interferon-Ineligible/Intolerant Individuals [J].
Hagan, Liesl M. ;
Sulkowski, Mark S. ;
Schinazi, Raymond F. .
HEPATOLOGY, 2014, 60 (01) :37-45
[4]   Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial [J].
Jacobson, Ira M. ;
Dore, Gregory J. ;
Foster, Graham R. ;
Fried, Michael W. ;
Radu, Monica ;
Rafalsky, Vladimir V. ;
Moroz, Larysa ;
Craxi, Antonio ;
Peeters, Monika ;
Lenz, Oliver ;
Ouwerkerk-Mahadevan, Sivi ;
De La Rosa, Guy ;
Kalmeijer, Ronald ;
Scott, Jane ;
Sinha, Rekha ;
Beumont-Mauviel, Maria .
LANCET, 2014, 384 (9941) :403-413
[5]  
Lawitz E, 2013, NEW ENGL J MED, V369, P678, DOI [10.1056/NEJMoa1214853, 10.1056/NEJMc1307641]
[6]   The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients [J].
Linas, Benjamin P. ;
Barter, Devra M. ;
Leff, Jared A. ;
DiLorenzo, Madeline ;
Schackman, Bruce R. ;
Horsburgh, Charles R. ;
Assoumou, Sabrina A. ;
Salomon, Joshua A. ;
Weinstein, Milton C. ;
Kim, Arthur Y. ;
Freedberg, Kenneth A. .
AIDS, 2014, 28 (03) :365-376
[7]   Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial [J].
Manns, Michael ;
Marcellin, Patrick ;
Poordad, Fred ;
Affonso de Araujo, Evaldo Stanislau ;
Buti, Maria ;
Horsmans, Yves ;
Janczewska, Ewa ;
Villamil, Federico ;
Scott, Jane ;
Peeters, Monika ;
Lenz, Oliver ;
Ouwerkerk-Mahadevan, Sivi ;
De La Rosa, Guy ;
Kalmeijer, Ronald ;
Sinha, Rekha ;
Beumont-Mauviel, Maria .
LANCET, 2014, 384 (9941) :414-426
[8]   Cost-Effectiveness of Sofosbuvir-Based Triple Therapy for Untreated Patients With Genotype 1 Chronic Hepatitis C [J].
Petta, Salvatore ;
Cabibbo, Giuseppe ;
Enea, Marco ;
Macaluso, Fabio Salvatore ;
Plaia, Antonella ;
Bruno, Raffaele ;
Gasbarrini, Antonio ;
Craxi, Antonio ;
Camma, Calogero .
HEPATOLOGY, 2014, 59 (05) :1692-1705
[9]   Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection [J].
Saab, S. ;
Gordon, S. C. ;
Park, H. ;
Sulkowski, M. ;
Ahmed, A. ;
Younossi, Z. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (06) :657-675
[10]  
Tice J., 2014, The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis c infection
1